Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Prostatic Neoplasms 3 Prostate Cancer Metastatic 2 Myasthenia Gravis 2 Multiple Myeloma 2 Waldenstrom Macroglobulinemia 1 Subcutaneous panniculitis-like T-cell lymphoma 1 Skin Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Pneumonia 1 Pituitary Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasm, Residual 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Lung Neoplasms 1 Lung Diseases, Interstitial 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Immunoblastic Lymphadenopathy 1 Enteropathy-Associated T-Cell Lymphoma 1 Dementia 1 Craniopharyngioma 1 Cognitive Dysfunction 1 Autoimmune Diseases 1 Arthritis, Rheumatoid 1 Adrenal Insufficiency 1

Interventions

ceftolozane, tazobactam drug combination 1 Prednisone 1 Clinical Protocols 1 Calcitriol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Pneumonia × Prednisone × Clear all

NCT04036721 2023-02-23

PROS-CONS

National Institute for Tuberculosis and Lung Diseases, Poland

Phase 4 Suspended

Lung Neoplasms, Pneumonia, Lung Diseases, Interstitial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡